MyFinsight
Home
Blog
About
Proceeds from the
issuance of common stock...
$291,477K
Proceeds from the
exercise of common stock...
$586K
Net cash provided by
financing activities
$292,160K
Effect of exchange rate
changes on cash, cash...
$104K
Increase in cash, cash
equivalents and restricted...
$46,312K
Canceled cashflow
$245,952K
Maturities of marketable
securities
$34,950K
Proceeds from sale of
property and equipment
$281K
Change in fair value of
contingent consideration...
$8,804K
Stock-based compensation
expense
$5,671K
Accrued expenses and
other current...
$3,348K
Other non-current
assets
-$1,469K
Depreciation and
amortization
$1,043K
Non-cash rent expense
$878K
Loss from disposal of
property and equipment
-$639K
Accretion of discount on
marketable securities
-$71K
Net cash (used in)
provided by investing...
-$211,444K
Net cash used in
operating activities
-$34,508K
Canceled cashflow
$35,231K
Canceled cashflow
$21,923K
Purchases of marketable
securities
$246,489K
Net loss
-$52,788K
Purchases of property and
equipment
$186K
Prepaid expenses and
other current assets
$1,591K
Lease liabilities
-$1,255K
Accounts payable
-$797K
Back
Back
Cash Flow
Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics, Inc. (ODTX)
source: myfinsight.com